Literature DB >> 27312795

Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.

Fabrice Jardin1, Anais Pujals2, Laura Pelletier2, Elodie Bohers1, Vincent Camus1, Sylvain Mareschal1, Sydney Dubois1, Brigitte Sola3, Marlène Ochmann4, François Lemonnier2, Pierre-Julien Viailly1, Philippe Bertrand1, Catherine Maingonnat1, Alexandra Traverse-Glehen4, Philippe Gaulard2, Diane Damotte5, Richard Delarue6, Corinne Haioun2, Christian Argueta7, Yosef Landesman7, Gilles Salles8, Jean-Philippe Jais9, Martin Figeac10, Christiane Copie-Bergman2, Thierry Jo Molina11, Jean Michel Picquenot1, Marie Cornic1, Thierry Fest4, Noel Milpied12, Emilie Lemasle1, Aspasia Stamatoullas1, Peter Moeller13, Martin J S Dyer14, Christer Sundstrom15, Christian Bastard1, Hervé Tilly1, Karen Leroy2.   

Abstract

Primary mediastinal B-cell lymphoma (PMBL) is an entity of B-cell lymphoma distinct from the other molecular subtypes of diffuse large B-cell lymphoma (DLBCL). We investigated the prevalence, specificity, and clinical relevance of mutations of XPO1, which encodes a member of the karyopherin-β nuclear transporters, in a large cohort of PMBL. PMBL cases defined histologically or by gene expression profiling (GEP) were sequenced and the XPO1 mutational status was correlated to genetic and clinical characteristics. The XPO1 mutational status was also assessed in DLBCL, Hodgkin lymphoma (HL) and mediastinal gray-zone lymphoma (MGZL).The biological impact of the mutation on Selective Inhibitor of Nuclear Export (SINE) compounds (KPT-185/330) sensitivity was investigated in vitro. XPO1 mutations were present in 28/117 (24%) PMBL cases and in 5/19 (26%) HL cases but absent/rare in MGZL (0/20) or DLBCL (3/197). A higher prevalence (50%) of the recurrent codon 571 variant (p.E571K) was observed in GEP-defined PMBL and was associated with shorter PFS. Age, International Prognostic Index and bulky mass were similar in XPO1 mutant and wild-type cases. KPT-185 induced a dose-dependent decrease in cell proliferation and increased cell-death in PMBL cell lines harboring wild type or XPO1 E571K mutant alleles. Experiments in transfected U2OS cells further confirmed that the XPO1 E571K mutation does not have a drastic impact on KPT-330 binding. To conclude the XPO1 E571K mutation represents a genetic hallmark of the PMBL subtype and serves as a new relevant PMBL biomarker. SINE compounds appear active for both mutated and wild-type protein. Am. J. Hematol. 91:923-930, 2016.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27312795     DOI: 10.1002/ajh.24451

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  35 in total

1.  Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade.

Authors:  Bjoern Chapuy; Chip Stewart; Andrew J Dunford; Jaegil Kim; Kirsty Wienand; Atanas Kamburov; Gabriel K Griffin; Pei-Hsuan Chen; Ana Lako; Robert A Redd; Claire M Cote; Matthew D Ducar; Aaron R Thorner; Scott J Rodig; Gad Getz; Margaret A Shipp
Journal:  Blood       Date:  2019-12-26       Impact factor: 22.113

2.  Prognostication with circulating tumor DNA: is it ready for prime time?

Authors:  David M Kurtz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

3.  Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.

Authors:  Kirsty Wienand; Bjoern Chapuy; Chip Stewart; Andrew J Dunford; David Wu; Jaegil Kim; Atanas Kamburov; Timothy R Wood; Fathima Zumla Cader; Matthew D Ducar; Aaron R Thorner; Anwesha Nag; Alexander T Heubeck; Michael J Buonopane; Robert A Redd; Kamil Bojarczuk; Lee N Lawton; Philippe Armand; Scott J Rodig; Jonathan R Fromm; Gad Getz; Margaret A Shipp
Journal:  Blood Adv       Date:  2019-12-10

Review 4.  Diagnosis and classification of hematologic malignancies on the basis of genetics.

Authors:  Justin Taylor; Wenbin Xiao; Omar Abdel-Wahab
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

Review 5.  The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.

Authors:  Jennifer R Landes; Stephen A Moore; Brooke R Bartley; Hung Q Doan; Peter L Rady; Stephen K Tyring
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-08       Impact factor: 4.322

6.  Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC).

Authors:  Misako Nagasaka; Mohammad Fahad B Asad; Mohammed Najeeb Al Hallak; Md Hafiz Uddin; Ammar Sukari; Yasmine Baca; Joanne Xiu; Dan Magee; Hirva Mamdani; Dipesh Uprety; Chul Kim; Bing Xia; Stephen V Liu; Jorge J Nieva; Gilberto Lopes; Gerold Bepler; Hossein Borghaei; Michael J Demeure; Luis E Raez; Patrick C Ma; Sonam Puri; W Michael Korn; Asfar S Azmi
Journal:  Lung Cancer       Date:  2021-08-27       Impact factor: 6.081

7.  Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

Authors:  Dan T Vogl; David Dingli; Robert Frank Cornell; Carol Ann Huff; Sundar Jagannath; Divaya Bhutani; Jeffrey Zonder; Rachid Baz; Ajay Nooka; Joshua Richter; Craig Cole; Ravi Vij; Andrzej Jakubowiak; Rafat Abonour; Gary Schiller; Terri L Parker; Luciano J Costa; David Kaminetzky; James E Hoffman; Andrew J Yee; Ajai Chari; David Siegel; Rafael Fonseca; Scott Van Wier; Gregory Ahmann; Ilsel Lopez; Michael Kauffman; Sharon Shacham; Jean-Richard Saint-Martin; Carla D Picklesimer; Cassandra Choe-Juliak; A Keith Stewart
Journal:  J Clin Oncol       Date:  2018-01-30       Impact factor: 44.544

Review 8.  The nuclear export protein XPO1 - from biology to targeted therapy.

Authors:  Asfar S Azmi; Mohammed H Uddin; Ramzi M Mohammad
Journal:  Nat Rev Clin Oncol       Date:  2020-11-10       Impact factor: 66.675

Review 9.  Karyopherins in cancer.

Authors:  Tolga Çağatay; Yuh Min Chook
Journal:  Curr Opin Cell Biol       Date:  2018-02-04       Impact factor: 8.382

10.  Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study.

Authors:  Erlene K Seymour; Husain Yar Khan; Yiwei Li; Mahmoud Chaker; Irfana Muqbil; Amro Aboukameel; Radhakrishanan Ramchandren; Christiane Houde; Golbon Sterbis; Jay Yang; Divaya Bhutani; Silvana Pregja; Kathy Reichel; Amy Huddlestun; Colleen Neveux; Kelly Corona; Yosef Landesman; Jatin Shah; Michael Kauffman; Sharon Shacham; Ramzi M Mohammad; Asfar S Azmi; Jeffrey A Zonder
Journal:  Clin Cancer Res       Date:  2021-03-30       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.